About us

Dr. Shamsuddin created a breakthrough technological discovery for the early detection of cancer… detecting cancer even at precancerous stages.

Dr. Kim Vanderlinden, Founder and CEO

Dr. Vanderlinden practiced for almost two decades. He is the founder of a science-based nutritional company. see www.HopeScience.com He also a degree has degree in Business Administration.

Gary McAdam, Founder and Consultant

Gary J. McAdam is the Founder and President of Growth Ventures Inc., 1986-present.

SCOTT PANTEL ,
Board Advisor

Scott is CEO of Life Science Intelligence (LSI), a leading medtech-focused market research and advisory firm. Scott is Founder of the US and European Emerging Medtech Summit’s.

DR. ELIJAH CARTER JR, DVM, MD, F.A.C.O.G BOARD MEMBER

Dr. Elijah Carter is a board certified Obstetrician and Gynecologist. After graduation he was inducted into the National Honor Medical Society.

DR. RYAN SPITLER PHD, BOARD MEMBER

Dr. Spitler is the Deputy Director & Co-founder of the Precision Health and Integrated Diagnostics Center (PHIND), Deputy Director of the Canary Center for Cancer Early Detection, and Program Manager for the International Alliance for Cancer Early Detection (ACED) at Stanford University.

7 MINUTE VIDEO FROM LSI MEDTECH CONFERENCE MAY 2021

Early Detection Inc. - Cancer Screening Test Presentation by Dr. Kim Vanderlinden

Dr. Shamsuddin created a breakthrough technological discovery for the early detection of cancer… detecting cancer even at precancerous stages.

Dr. Shamsuddin received his medical degree from the University of Dhaka, Bangladesh and received a PhD in cancer research from the University of Maryland, Baltimore. He is a trained pathologist, certified by the American Board of Pathology and for over 40 years was a professor of Pathology at the University of Maryland School of Medicine.

As a pathologist, he had seen the ravages of cancer on a daily basis, besides that, he had lost his father and an uncle soon after their diagnosis. Thus his primary goal in cancer research has been early detection and prevention of cancer. Towards that aim, he extensively studied early stages of cancer formation using various experimental models in the lab and compared the findings to human disease for over a decade. He identified that a "sugar" normally present in most of our cells and their secretions is altered very early in cancer formation and invented a rapid, simple, inexpensive yet accurate point-of-care test for cancer screening.

Though at the beginning he used colorectal cancer as a model, subsequent studies over the next decade demonstrated that the same marker and the technology is applicable in breast, lungs, prostate, uterus, pancreas, etc. Nearly 27 independent clinical studies validate the ability of the tests to accurately identify cancers early in these organs. Dr. Shamsuddin has published over 200 peer-reviewed papers, abstracts, book-chapters, and books; and is a well sought-after speaker throughout the world.

Dr. Vanderlinden entered medicine after seeing his mother overcome a terminal Hodgkin's lymphoma diagnosis when he was a teenager. Then several years later, and only months after graduating his mother died of lung cancer. It is said that loss can lead to purpose, which it truly did for him, and ultimately to the formation of Early Detection, Inc.

He feels truly humbled to be able to contribute to making this screening test available to physicians and their patients. Dr. Vanderlinden expects that these tests will become an essential component of annual physical exams. Yearly exams attempt to find disorders early so that they can be prevented and/or treated more effectively. For example, blood pressure and cholesterol are measured in order to more successfully manage cardiovascular risk of heart attacks and strokes.

He believes that a lack of a screening test for early cancer detection is the single greatest void in healthcare today. In time he expects annual physical exams without these screening tests will be considered undeniably incomplete.

Dr. Vanderlinden's mother died of lung cancer in her 50s, his only aunt died of breast cancer in her early 40s and his only cousin also died of breast cancer in her late 30s. If this test would have only been available at the time, his family would not have been so severely ravaged by cancer.

Gary J. McAdam is the Founder and President of Growth Ventures Inc., 1986-present.

Mr. McAdam is skilled in corporate structuring, business, strategic, and financial planning, capital formation, structuring and implementing merger and acquisition transactions. He is adept in assembling human resources including board members, management members, employees, business consultants, and advisors including investor relations, public relations, legal, accounting, auditing, and transfer agent services.

He has helped numerous companies with their corporate structure, and positioned them for financings and in arranging for and assisting management with appropriate individual and corporate investors and investment bankers.

Mr. McAdam has extensive experience transitioning companies from the private sector into the public sector through the merger process or via an IPO.

As Founder and President of Growth Ventures, Inc. (GVI), Mr. McAdam has conducted significant business consulting, strategic and capital advising, and merger and acquisition transactions. Have founded numerous companies and consulted with and participated in over 50 merger and acquisition transactions with private and public companies in a variety of industries. GVI and its Founder have been involved from inception or early stage with companies that have progressed to attract over $1 billion in equity financings.

Scott is CEO of Life Science Intelligence (LSI), a leading medtech-focused market research and advisory firm. Scott is Founder of the US and European Emerging Medtech Summit’s. He also serves as a Board Advisor to early-stage medtech startups, venture funds, and healthcare SPACs. Scott has been the CEO of LSI and advisor in the medtech industry for over 20 years and has managed over 200 consulting engagements for major strategics.

Dr. Elijah Carter is a board certified Obstetrician and Gynecologist. After graduation he was inducted into the National Honor Medical Society. He maintained a private practice from 1984 -2001. Group OB/GYN Medical Practice Associations followed until 2016. Since then, he has pursued his growing interest in Preventative and Restorative Medicine.

Dr. Carter is a passionate lecturer on Cellular Anatomy and Physiology, Cellular Nutrition, Bio-identical Hormones, Antioxidants, the Elements, Essential Oils, EME and Positive Thinking.

He is the inventor of The Carter Tubal Assistant for PostpartumTubal ligation.

Dr. Spitler is the Deputy Director & Co-founder of the Precision Health and Integrated Diagnostics Center (PHIND), Deputy Director of the Canary Center for Cancer Early Detection, and Program Manager for the International Alliance for Cancer Early Detection (ACED) at Stanford University. Dr. Spitler is also a founding Partner at Boutique Venture Partners, an early-stage venture capital firm specializing in healthcare, life sciences, and medtech.He has served as teaching faculty for the Stanford Byers Center for Bio-design, completed executive training programs at Stanford school of business and Bio-design, and completed a Post Doctorial Research Fellowship in synthetic biology and radiology at Stanford School of Medicine. He has developed and launched several new approaches working across multiple scientific areas ranging from medical devices to gene therapies. Prior to Stanford, Dr. Spitler completed a Ph.D. in Cellular and Developmental Biology at the Beckman Laser Institute at the University of California, Irvine and B.S. in Molecular Cell and Developmental Biology from the University of California, Santa Cruz. Over the past two decades he has held several academic and industrial positions and has served as a board member and/or advisor for a number of Bay Area companies.Dr. Spitler is the recipient of the Top 25 voices in Precision Medicine award, Stanford Radiological Sciences Laboratory Innovation Challenge Award, Stanford Cancer Imaging Fellowship Training Award, Biophotas Research Fellowship, and the Stanford Center for Biomedical Imaging Achievement Award. He has numerous scientific articles and books across many different disciplines.